A Randomized ,Open Label Study Comparing the Efficacy of Zoladex Combined With Arimidex for 3-2 Years After Selective Estrogen Receptor Modulators (SERMs) as an Adjuvant Therapy for 2-3 Years Versus Continuing Tamoxifen up to 5 Years for Premenopausal Early Breast Cancer Patients With Hormone Receptor Positive, Lymph Node Positive or Tumor >=4cm.
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Goserelin (Primary) ; Anastrozole; Tamoxifen
- Indications Early breast cancer
- Focus Therapeutic Use
- 14 May 2011 New trial record